J&J bids $6.5 billion for Momenta

19 August 2020
jnjn_flickr_big

Shares of US biotech Momenta Pharmaceuticals (Nasdaq: MNTA) raced up 70% to $52.44 in pre-market trading this morning, after it was revealed that it had agree to be acquired by healthcare giant Johnson & Johnson (NYSE: JNJ).

Under the definitive agreement, J&J will buy the company in an all cash transaction for $52.50 per share, representing a total equity value of $6.5 billion and a 70% premium to Momenta’s closing price on August 18, 2020

This acquisition provides an opportunity for the J&J Janssen Pharmaceutical Companies to broaden leadership in immune-mediated diseases and drive further growth through expansion into autoantibody-driven disease.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology